Hedge Fund News: Jim Chanos, Davidson Kempner & Jana Partners

Page 1 of 2

Masters in Business: James Chanos (BloombergView)
Hedge-fund manager James Chanos of Kynikos Associates describes how he became a “fundamental short seller” in this week’s “Masters in Business” podcast. Listen to the full interview here. Early in his career as an equity analyst at Gilford Securities, he discovered that Baldwin Piano had morphed into a seller of insurance annuities and was also becoming a serial acquirer of other insurers. But the numbers didn’t add up. Chanos kept asking questions, eventually leading to the discovery that earnings were being pulled forward, creating very misleading numbers…

Jim Chanos on china map

Point72’s President Thomas Conheeney to quit (Fortune)
Point72 Asset Management’s President Thomas Conheeney will leave the hedge fund giant, according to reports. Founded by Steven A. Cohen in 1992, the hedge fund has seen eight current or former employees convicted on criminal charges related to insider trading, The Wall Street Journal said. Earlier this year the fund changed its name from SAC Capital Advisors LP to Point72 Asset Management.

Davidson Kempner Makes the Most of Multistrategy Model (InstitutionalInvestorsAlpha)
A summary of Davidson Kempner Capital Management’s portfolio in the second quarter reveals that the firm made money in each of the first six months this year, a feat few funds can claim in this roller-coaster year for many of the world’s markets, according to a document offering a rare peek into the historically opaque firm. The New York-based multistrategy hedge fund fund firm has posted a 6.3 percent gain in the first half of the year, with relatively low volatility compared with other hedge funds.

Steadfast Sues Texas O&G Investment Firm Over Trademark (Law360)
Hedge fund manager Steadfast Financial LP hit oil and gas financial services firm Steadfast Financial LLC with a trademark infringement suit in Texas federal court on Friday, arguing an ongoing suit against the latter has harmed the hedge fund manager’s reputation. Plaintiffs Steadfast Financial LP and its affiliated Steadfast Capital Management LP say they own an “incontestable” registered mark for “Steadfast” for “financial services, namely, financial analysis and consultation, forecasting and research, and financial investments in the field of mutual funds, hedge funds and private equity…

Liberal Billionaire: 99.5% of Americans Are Not ‘Super Sophisticated’ (CNSNews)
Billionaire hedge-fund manager Tom Steyer attempted to explain why there is still a sizable portion of Americans that do not buy in to global warming alarmism by, basically, generalizing virtually all of America as not “super sophisticated.” Speaking at a climate conference hosted by the American Renewable Energy Institute, Steyer said: “I think if you were to go around to most of the — what I would think of as super-sophisticated people who think about politics and policy more than five minutes a month — we are doing really well.”

Hedge Funds Lose Appeal In Porsche Suit (HedgeCo)
Porsche has won a case in the US appeals court put forward by a group of over 30 hedge funds led by Greenlight Capital, Elliott International and Perry Partners, who tried to sue the carmakers for 1.81 billion euros (approximately $2.4 billion), Reuters reports. The news source said: “The 2nd U.S. Circuit Court of Appeals on Friday [Aug. 15] said Porsche’s alleged wrongdoing was “so predominantly foreign” that it could not be held liable in U.S. federal courts under domestic securities fraud laws. It also said that the hedge funds might still “conceivably” show that U.S. laws should apply, and try to amend their lawsuit in Manhattan federal court.”

Market jitters: Energy & equities (CNBC)

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!